Abstract
In this issue of Blood, Althaus et al identify circulating procoagulant platelets as a novel biomarker of COVID-19 disease severity and present provocative in vitro findings demonstrating that antibodies induced in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can initiate procoagulant platelet formation.
MeSH terms
-
COVID-19*
-
Humans
-
SARS-CoV-2